A pair of top-line datasets from what analysts called a successful phase III trial in allergic conjunctivitis and a phase IIb study said to have done its job in glaucoma/ocular hypertension (OH) apparently didn't convince investors in Ocular Therapeutix Inc., who took shares (NASDAQ:OCUL) down 52.3 percent Friday, or $7.88, to close at $7.18.